by Max Verhage | Mar 13, 2026 | Blog
Not every promising discovery needs its own company. But making the right venture decision in socially responsible drug development is one of the most consequential choices an academic researcher, clinician, or principal investigator will face. In socially responsible...
by Max Verhage | Feb 5, 2026 | Blog
You probably recognise this situation. You have strong science, promising early data, and a clear potential to help patients. Yet the project risks stalling before it reaches the clinic. Or it moves forward in a way that promises a long and torturous road to get...
by Max Verhage | Dec 9, 2025 | Blog
You’ve spent years developing a promising compound as a professor, clinician, or researcher. The preclinical data looks solid. There’s clear potential to help patients with an unmet medical need. But now you face a tough question: how do you get your...
by Barbara Van den Aarsen | Nov 12, 2025 | Blog
What is a Paediatric Investigation Plan (PIP)? The European Medicines Agency (EMA) requires sponsors to follow Paediatric Investigation Plan (PIP) guidelines as part of the regulatory process for developing medicines intended for children. While other regulatory...
by Max Verhage | Oct 6, 2025 | Blog
Cystinosis is a rare hereditary disease which leads to accumulation of cystine in the lysosomes causing organ failure. The disease manifests in all organs, but the kidneys and the eyes are affected first. Even though for cystinosis there is a therapy available,...
by Barbara Van den Aarsen | Sep 12, 2025 | Blog
Investigator-initiated clinical trials trials play an important role in advancing medical knowledge, exploring novel uses for existing therapies, and addressing clinically relevant questions that industry trials may overlook. However, these trials come with unique...
